BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32344513)

  • 1. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
    Li C; Li T; Huang L; Yang M; Zhu G
    Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
    Shang XB; Yu ZT; Tang P; Zhang XZ
    Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
    Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
    Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The knock-down of ERCC1 but not of XPF causes multinucleation.
    Rageul J; Frëmin C; Ezan F; Baffet G; Langouët S
    DNA Repair (Amst); 2011 Sep; 10(9):978-90. PubMed ID: 21839691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M; Linardou H; Alvisi MF; Caiola E; Lo Russo G; Cecere FL; Bettini AC; Psyrri A; Milella M; Rulli E; Fabbri A; De Maglie M; Romanelli P; Murray S; Broggini M; Marabese M; Garassino MC
    ESMO Open; 2021 Feb; 6(1):100034. PubMed ID: 33422766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
    He L; Wang X; Liu K; Wu X; Yang X; Song G; Zhang B; Zhong L
    Gene; 2019 Apr; 691():70-76. PubMed ID: 30584903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
    Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing gene 1 in lung cancer cell A549/DDP].
    Gao Y; Su D; Ying L; Lv W; Ma S
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):846-9. PubMed ID: 20840811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K; Melton DW
    Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.